Strongbridge Biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Strongbridge Biopharma generated cash of -$38,134,000, which is more than the previous year. Cash used in financing activities reached the amount of $47,512,000 last year. Net change in cash is therefore $30,490,000.
Cash Flow
| 2013 | -3.47M | -2K | 14.92M |
|---|---|---|---|
| 2014 | -15.66M | -3.19M | 58.29M |
| 2015 | -37.36M | -4.29M | 77.40M |
| 2016 | -31.71M | -3.39M | 50.32M |
| 2017 | -45.33M | -7.5M | 43.50M |
| 2018 | -84.57M | 134.33M | 15.22M |
| 2019 | -44.78M | -20.76M | 87K |
| 2020 | -38.13M | 21.11M | 47.51M |
SBBP Cash Flow Statement (2013 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 57.03M | 122.49M | 57.51M | 66.83M | 51.62M | 15.63M | 15.63M | 3.90M |
Operating activities | ||||||||
Net income | -45.07M | -49.45M | 31.85M | -113.48M | -48.59M | -43.58M | -9.67M | -5.29M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 5.10M | 5.09M | 7.23M | 5.03M | 10K | 11K | 6K | 3K |
Stock-based compensation expense | 7.38M | 8.59M | 7.80M | 5.16M | 4.60M | 3.94M | 2.81M | 748K |
| Deferred income tax benefit | 7.38M | 8.59M | 7.80M | 5.16M | 4.60M | 3.94M | 2.81M | 748K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -512K | -663K | -42K | -1.58M | 0 | 0 | 0 | 0 |
Inventories | 1.06M | 1.61M | -3.43M | -511K | 0 | 0 | 0 | 0 |
Accounts payable | -1.84M | 2.15M | -63K | 158K | -1.70M | 1.73M | 0 | 519K |
Cash generated by operating activities | -38.13M | -44.78M | -84.57M | -45.33M | -31.71M | -37.36M | -15.66M | -3.47M |
Investing activities | ||||||||
Purchases Of Investments | 0 | -56.18M | 0 | 0 | 0 | -1.10M | 0 | 0 |
Investments In Property Plant And Equipment | -10K | -74K | -326K | 0 | 0 | -25K | -25K | -2K |
Acquisitions Net | 0 | 0 | 135M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 21.11M | -20.76M | 134.33M | -7.5M | -3.39M | -4.29M | -3.19M | -2K |
Financing activities | ||||||||
Common Stock Issued | 28.60M | 0 | 64.48M | 26.45M | 32.29M | 77.81M | 58.29M | 14.92M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -1.41M | -412K | 0 | 0 |
Repayments of term debt | 0 | 0 | -94.99M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 47.51M | 87K | 15.22M | 43.50M | 50.32M | 77.40M | 58.29M | 14.92M |
Net Change In Cash | 30.49M | -65.45M | 64.98M | -9.32M | 15.21M | 35.99M | 38.75M | 10.99M |
Cash at end of period | 87.52M | 57.03M | 122.49M | 57.51M | 66.83M | 51.62M | 54.38M | 14.89M |
| Data source | Data source | Data source | Data source |